Octagon Welcomes new Managing Director of European Operations
News Jan 13, 2006
Octagon Research Solutions has named Mark Turner as managing director of its European operations.
Octagon Research Solutions opened its European headquarters in Amersham, UK, this past June in response to increasing demand for European support from its global customers.
Mr. Turner will oversee Octagon’s European headquarters and will be responsible for leading the strategic planning, development and deployment of Octagon’s capabilities to support clients throughout Europe with a specific emphasis on regulatory strategies.
"Octagon has really revolutionized the electronic submission process within the clinical R&D space," said Mr. Turner.
"I look forward to helping companies throughout Europe benefit from Octagon’s impressive portfolio of services and solutions."
Mr. Turner has 14 years of regulatory experience in the United Kingdom. He has also served in many leadership roles including the director of worldwide regulatory affairs for Zeneus Pharma Limited in Oxfordshire, UK, and as the European Union (EU) and international regulatory affairs director for Elan Pharma Limited (UK)/Elan Pharma International Limited in Hertfordshire, UK.
Mr. Turner holds a bachelor of science degree in physiology with pharmacology from the University of Southampton. He is currently a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).
"We are extremely excited to have Mark on board and we consider his appointment a critical milestone in the strategic development of our European operations," explained James Walker, president and CEO.
"Mark’s extensive regulatory experience makes him an ideal person to spearhead our European expansion and we are certain that our global customers will benefit from his experience and contributions to Octagon’s level of service, expertise and innovative solutions."
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE
GE Focuses Portfolio for Growth and Shareholder Value CreationNews
Healthcare to become standalone company; GE expects to monetize 20% and distribute remaining 80% of GE Healthcare to shareholders tax-free.READ MORE